Regulatory factors involved in Th17/Treg cell balance of immune thrombocytopenia.

[1]  Ziming Huang,et al.  Research on the mechanism of prednisone in the treatment of ITP via VIP/PACAP-mediated intestinal immune dysfunction , 2023, European Journal of Medical Research.

[2]  B. Malissen,et al.  IL-2 and IL-15 drive intrathymic development of distinct periphery-seeding CD4+Foxp3+ regulatory T lymphocytes , 2022, Frontiers in Immunology.

[3]  Lan-lan Zhong,et al.  [Expression of miR-106b-5p in children with primary immune thrombocytopenia and its correlation with T cells]. , 2022, Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics.

[4]  G. Le Menn,et al.  The effects of post-translational modifications on Th17/Treg cell differentiation. , 2022, Biochimica et biophysica acta. Molecular cell research.

[5]  R. Xu,et al.  The Extensive Regulation of MicroRNA in Immune Thrombocytopenia , 2022, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[6]  Shaoyan Hu,et al.  HUWE1 Causes an Immune Imbalance in Immune Thrombocytopenic Purpura by Reducing the Number and Function of Treg Cells Through the Ubiquitination Degradation of Ets-1 , 2021, Frontiers in Cell and Developmental Biology.

[7]  Michael R Hamblin,et al.  Dysregulated expression of miRNAs in immune thrombocytopenia. , 2021, Epigenomics.

[8]  Yunfeng Cheng,et al.  Decreased levels of immune‐regulatory cytokines in patients with immune thrombocytopenia and long‐lasting overexpression of these cytokines in the splenectomized patients , 2021, Journal of leukocyte biology.

[9]  Yuting Gu,et al.  miR-99a regulates CD4+ T cell differentiation and attenuates experimental autoimmune encephalomyelitis by mTOR-mediated glycolysis , 2021, Molecular therapy. Nucleic acids.

[10]  A. Asnafi,et al.  Prevalence of Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Subclinical Infection in Patients with Acute Immune Thrombocytopenic Purpura (ITP) , 2021, International Journal of Hematology-Oncology and Stem Cell Research.

[11]  B. Bonnotte,et al.  Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments , 2021, HemaSphere.

[12]  Yiping Hu,et al.  Expression and function of Smad7 in autoimmune and inflammatory diseases , 2021, Journal of Molecular Medicine.

[13]  Guoan Chen,et al.  Bone marrow mesenchymal stem cell-derived exosomes induce the Th17/Treg imbalance in immune thrombocytopenia through miR-146a-5p/IRAK1 axis , 2021, Human Cell.

[14]  Huimin Hu,et al.  Increased proportion of Th17/Treg cells at the new diagnosed stage of chronic immune thrombocytopenia in pediatrics: the pilot study from a multi-center , 2021, European Journal of Pediatrics.

[15]  M. Zhang,et al.  Bach2 attenuates IL-2R signaling to control Treg homeostasis and Tfr development. , 2021, Cell reports.

[16]  Je-Min Choi,et al.  In Vivo Induction of Regulatory T Cells Via CTLA‐4 Signaling Peptide to Control Autoimmune Encephalomyelitis and Prevent Disease Relapse , 2021, Advanced science.

[17]  Shaoyan Hu,et al.  Extracellular vesicles derived from miR-199a-5p-modified adipose-derived mesenchymal stem cells alleviate immune thrombocytopenia by inhibiting T helper 17 differentiation , 2021, Laboratory Investigation.

[18]  Liqin Zhang,et al.  Decreasing lncRNA PVT1 causes Treg/Th17 imbalance via NOTCH signaling in immune thrombocytopenia , 2021, Hematology.

[19]  S. Kaneko,et al.  Notch Signaling and Liver Cancer. , 2021, Advances in experimental medicine and biology.

[20]  Zhi-yun Chen,et al.  The Function and Role of the Th17/Treg Cell Balance in Inflammatory Bowel Disease , 2020, Journal of immunology research.

[21]  P. Duquette,et al.  Interleukin-15 enhances proinflammatory T-cell responses in patients with MS and EAE , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[22]  J. Bussel,et al.  Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment , 2020, American journal of hematology.

[23]  Xin He,et al.  Th17/Treg Imbalance and Atherosclerosis , 2020, Disease markers.

[24]  F. Hua,et al.  The correlation between the Th17/Treg cell balance and bone health , 2020, Immunity & ageing : I & A.

[25]  B. H. Ng,et al.  Treg Enhancing Therapies to Treat Autoimmune Diseases , 2020, International journal of molecular sciences.

[26]  Devin M. Jones,et al.  Dynamic Roles for IL-2–STAT5 Signaling in Effector and Regulatory CD4+ T Cell Populations , 2020, The Journal of Immunology.

[27]  A. Waisman,et al.  PKM2 promotes Th17 cell differentiation and autoimmune inflammation by fine-tuning STAT3 activation , 2020, The Journal of experimental medicine.

[28]  N. Zivkovic,et al.  IMMUNOMODULATORY EFFECTS OF TGF-β IN THE PATIENTS WITH IMMUNE THROMBOCYTOPENIA , 2020, Acta Medica Medianae.

[29]  C. Feng,et al.  Regulation of T Helper Cell Fate by TCR Signal Strength , 2020, Frontiers in Immunology.

[30]  Yeongseon Byeon,et al.  Recent insights of T cell receptor-mediated signaling pathways for T cell activation and development , 2020, Experimental & Molecular Medicine.

[31]  J. Ling,et al.  miR-106b-5p induces immune imbalance of Treg/Th17 in immune thrombocytopenic purpura through NR4A3/Foxp3 pathway , 2020, Cell cycle.

[32]  Xiang Hu,et al.  Dexamethasone suppresses the Th17/1 cell polarization in the CD4+ T cells from patients with primary immune thrombocytopenia. , 2020, Thrombosis research.

[33]  Shaoyan Hu,et al.  [Pathogenesis of Immune Thrombocytopenic Purpura (ITP) by MiRNA-30a-Mediated Th17 Cell Differentiation]. , 2020, Zhongguo shi yan xue ye xue za zhi.

[34]  G. Martinelli,et al.  Linear and circular PVT1 in hematological malignancies and immune response: two faces of the same coin , 2020, Molecular Cancer.

[35]  M. Schmugge,et al.  Increased levels of IL-10 and IL-1Ra counterbalance the proinflammatory cytokine pattern in acute pediatric immune thrombocytopenia. , 2020, Cytokine.

[36]  G. Tye,et al.  Interleukin 23 and autoimmune diseases: current and possible future therapies , 2020, Inflammation Research.

[37]  N. Zivkovic,et al.  CD4+ T cell phenotypes in the pathogenesis of immune thrombocytopenia. , 2020, Cellular immunology.

[38]  Hongwei Chen,et al.  miR-106b-5p promotes cell proliferation and cell cycle progression by directly targeting CDKN1A in osteosarcoma , 2020, Experimental and therapeutic medicine.

[39]  Wei Yang,et al.  Protein Kinase 2 (CK2) Controls CD4+ T-cell Effector Function in the Pathogenesis of Colitis , 2020, Mucosal Immunology.

[40]  S. Sakaguchi,et al.  Impaired T cell receptor signaling and development of T cell–mediated autoimmune arthritis , 2020, Immunological reviews.

[41]  David Chisanga,et al.  Attenuation of TCR-induced transcription by Bach2 controls regulatory T cell differentiation and homeostasis , 2020, Nature Communications.

[42]  J. Semple,et al.  Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP) , 2020, Platelets.

[43]  Kuender D Yang,et al.  Intravenous immunoglobulin therapy enhances suppressive regulatory T cells and decreases innate lymphoid cells in children with immune thrombocytopenia , 2019, Pediatric blood & cancer.

[44]  Shuang Liu,et al.  Disrupted balance of CD4+ T-cell subsets in bone marrow of patients with primary immune thrombocytopenia , 2019, International journal of biological sciences.

[45]  Y. Liu,et al.  PD-1/PD-L1 pathway activation restores the imbalance of Th1/Th2 and treg/Th17 cells subtypes in immune thrombocytopenic purpura patients , 2019, Medicine.

[46]  Yingyuan Yu,et al.  IL-21 Induces an Imbalance of Th17/Treg Cells in Moderate-to-Severe Plaque Psoriasis Patients , 2019, Front. Immunol..

[47]  Fu-ming Zi,et al.  The potential therapeutic benefit of resveratrol on Th17/Treg imbalance in immune thrombocytopenic purpura. , 2019, International immunopharmacology.

[48]  H. Nagase,et al.  Forced expression of NR4A3 induced the differentiation of human neuroblastoma-derived NB1 cells , 2019, Medical Oncology.

[49]  M. Hou,et al.  Aberrant expression of microRNA in CD4+ cells contributes to Th17/Treg imbalance in primary immune thrombocytopenia. , 2019, Thrombosis research.

[50]  C. Klein,et al.  Genetic Deficiency and Biochemical Inhibition of ITK Affect Human Th17, Treg, and Innate Lymphoid Cells , 2019, Journal of Clinical Immunology.

[51]  J. Buteau,et al.  The orphan nuclear receptor Nor1/Nr4a3 is a negative regulator of β-cell mass , 2019, The Journal of Biological Chemistry.

[52]  Xiurong Li,et al.  PD-1/PD-L Pathway Potentially Involved in ITP Immunopathogenesis , 2018, Thrombosis and Haemostasis.

[53]  J. Seghatchian,et al.  Flow cytometry and immune thrombocytopenic purpura. , 2018, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[54]  Ting Wang,et al.  MicroRNA‐mediated regulation of T helper type 17/regulatory T‐cell balance in autoimmune disease , 2018, Immunology.

[55]  J. Vela-Ojeda,et al.  Description of CD8+ Regulatory T Lymphocytes and Their Specific Intervention in Graft-versus-Host and Infectious Diseases, Autoimmunity, and Cancer , 2018, Journal of immunology research.

[56]  A. Waisman,et al.  Expression of IL-17F is associated with non-pathogenic Th17 cells , 2018, Journal of Molecular Medicine.

[57]  Yiping Wang,et al.  Low dose IL‐2 increase regulatory T cells and elevate platelets in a patient with immune thrombocytopenia , 2018, Cytometry. Part B, Clinical cytometry.

[58]  D. Elston,et al.  When worlds collide: Th17 and Treg cells in cancer and autoimmunity , 2018, Cellular & Molecular Immunology.

[59]  Greg M. Delgoffe,et al.  IL-23 and IL-1β Drive Human Th17 Cell Differentiation and Metabolic Reprogramming in Absence of CD28 Costimulation. , 2018, Cell reports.

[60]  R. Talukdar,et al.  Bach2 repression mediates Th17 cell induced inflammation and associates with clinical features of advanced disease in chronic pancreatitis , 2018, United European gastroenterology journal.

[61]  Yiping Wang,et al.  Immune dysregulation in primary immune thrombocytopenia patients , 2018, Hematology.

[62]  C. Nielsen,et al.  Reconstitution of Th17, Tc17 and Treg cells after paediatric haematopoietic stem cell transplantation: Impact of interleukin-7. , 2018, Immunobiology.

[63]  Jiamin Zhang,et al.  Mesenchymal stem cell deficiency influences megakaryocytopoiesis through the TNFAIP3/NF‐κB/SMAD pathway in patients with immune thrombocytopenia , 2018, British journal of haematology.

[64]  Wenying Yan,et al.  Differential Expression of MiR-106b-5p and MiR-200c-3p in Newly Diagnosed Versus Chronic Primary Immune Thrombocytopenia Patients Based on Systematic Analysis , 2018, Cellular Physiology and Biochemistry.

[65]  Y. Liu,et al.  Percentages of PD-1+CD4+T cells and PD-L1+DCs are increased and sPD-1 level is elevated in patients with immune thrombocytopenia , 2018, Human vaccines & immunotherapeutics.

[66]  Jun-hao Chen,et al.  Circulating level of Th17 cells is associated with sensitivity to glucocorticoids in patients with immune thrombocytopenia , 2018, International Journal of Hematology.

[67]  Wei Zhao,et al.  Th17/Treg dysregulation in allergic asthmatic children is associated with elevated notch expression , 2018, The Journal of asthma : official journal of the Association for the Care of Asthma.

[68]  Keji Zhao,et al.  The transcription factor Bhlhe40 is a switch of inflammatory versus antiinflammatory Th1 cell fate determination , 2017, The Journal of experimental medicine.

[69]  Min Kyung Kim,et al.  Casein kinase 2 is a critical determinant of the balance of Th17 and Treg cell differentiation , 2017, Experimental &Molecular Medicine.

[70]  Yusuke Minato,et al.  The cytokine polymorphisms affecting Th1/Th2 increase the susceptibility to, and severity of, chronic ITP , 2017, BMC Immunology.

[71]  Y. Okamoto,et al.  Th2 Cells in Health and Disease. , 2017, Annual review of immunology.

[72]  C. Ruan,et al.  Plasma microRNAs characterising patients with immune thrombo cytopenic purpura , 2017, Thrombosis and Haemostasis.

[73]  Shuang Liu,et al.  Cytokine changes in response to TPO receptor agonist treatment in primary immune thrombocytopenia , 2017, Cytokine.

[74]  Ping Zhang,et al.  Assessment of Th17/Treg cells and Th cytokines in an improved immune thrombocytopenia mouse model , 2017, Hematology.

[75]  J. Semple,et al.  Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP) , 2017, Journal of clinical medicine.

[76]  Z. Li,et al.  The aberrant expression of microRNAs and correlations with T cell subsets in patients with immune thrombocytopenia , 2016, Oncotarget.

[77]  M. Hou,et al.  Pulsed high-dose dexamethasone modulates Th1-/Th2-chemokine imbalance in immune thrombocytopenia , 2016, Journal of Translational Medicine.

[78]  Jing Lin,et al.  Long non-coding RNA MEG3 inhibits microRNA-125a-5p expression and induces immune imbalance of Treg/Th17 in immune thrombocytopenic purpura. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[79]  T. Mimori,et al.  GM-CSF as a therapeutic target in autoimmune diseases , 2016, Inflammation and regeneration.

[80]  T. Kühne,et al.  Thrombopoietin receptor agonists: a new immune modulatory strategy in immune thrombocytopenia? , 2016, Seminars in hematology.

[81]  Xiao Li,et al.  Interleukin-17-producing CD4+ T lymphocytes are increased in patients with primary immune thrombocytopenia , 2016, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[82]  L. Tuosto,et al.  CD28 costimulatory signals in T lymphocyte activation: Emerging functions beyond a qualitative and quantitative support to TCR signalling. , 2016, Cytokine & growth factor reviews.

[83]  M. Hou,et al.  T cells in the pathogenesis of immune thrombocytopenia. , 2016, Seminars in hematology.

[84]  Shaohua Chen,et al.  Lower expression of PD-1 and PD-L1 in peripheral blood from patients with chronic ITP , 2016, Hematology.

[85]  L. Fiette,et al.  IL-15-dependent balance between Foxp3 and RORγt expression impacts inflammatory bowel disease , 2016, Nature Communications.

[86]  Dina A. Ezzat,et al.  Correlation of Notch1/Hes1 Genes Expression Levels in Egyptian Paediatric Patients with Newly Diagnosed and Persistent Primary Immune(Idiopathic) Thrombocytopenic Purpura , 2016, Indian Journal of Hematology and Blood Transfusion.

[87]  S. Landas,et al.  Functional and Phenotypic Plasticity of CD4+ T Cell Subsets , 2015, BioMed research international.

[88]  James McCluskey,et al.  T cell receptor reversed polarity recognition of a self-antigen major histocompatibility complex , 2015, Nature Immunology.

[89]  J. Scheller,et al.  Insights into IL-23 biology: From structure to function. , 2015, Cytokine & growth factor reviews.

[90]  K. Kretschmer,et al.  Induced miR‐99a expression represses Mtor cooperatively with miR‐150 to promote regulatory T‐cell differentiation , 2015, The EMBO journal.

[91]  Jing Lin,et al.  MicroRNA-125-5p targeted CXCL13: a potential biomarker associated with immune thrombocytopenia. , 2015, American journal of translational research.

[92]  Tao Wu,et al.  [Effects of the interleukin-21 expression in patients with immune thrombocytopenia and its regulation by high-dose dexamethasone]. , 2015, Zhongguo shi yan xue ye xue za zhi.

[93]  D. Ma,et al.  Inactivation of Notch signaling reverses the Th17/Treg imbalance in cells from patients with immune thrombocytopenia , 2015, Laboratory Investigation.

[94]  Yan Chen,et al.  The Role of IL-23/Th17 Pathway in Patients with Primary Immune Thrombocytopenia , 2015, PloS one.

[95]  B. Seddon,et al.  Differential Requirement for IL-2 and IL-15 during Bifurcated Development of Thymic Regulatory T Cells , 2014, The Journal of Immunology.

[96]  B. Hahn,et al.  Th17 cells in inflammation and autoimmunity. , 2014, Autoimmunity reviews.

[97]  C. Zielinski.  Autoimmunity beyond Th17: GM-CSF producing T cells , 2014, Cell cycle.

[98]  M. El-Shahat,et al.  Alterations in immune cell subsets and their cytokine secretion profile in childhood idiopathic thrombocytopenic purpura (ITP) , 2014, Clinical and experimental immunology.

[99]  E. Shevach,et al.  tTregs, pTregs, and iTregs: similarities and differences , 2014, Immunological reviews.

[100]  H. Bai,et al.  Increased percentages of T cells producing interleukin‐21 in patients with immune thrombocytopenic purpura , 2014, Cell biology international.

[101]  Y. Belkaid,et al.  Itk-mediated integration of T cell receptor and cytokine signaling regulates the balance between Th17 and regulatory T cells , 2014, The Journal of experimental medicine.

[102]  L. Turka,et al.  Signals and pathways controlling regulatory T cells , 2014, Immunological reviews.

[103]  A. Lazarus,et al.  Amelioration of Murine Passive Immune Thrombocytopenia by IVIg and a Therapeutic Monoclonal CD44 Antibody Does Not Require the Myd88 Signaling Pathway , 2013, PloS one.

[104]  F. Marincola,et al.  BACH2 represses effector programmes to stabilize Treg-mediated immune homeostasis - a new target in tumor immunotherapy? , 2013, Journal of Immunotherapy for Cancer.

[105]  I. Nookaew,et al.  MicroRNA regulate immunological pathways in T-cells in immune thrombocytopenia (ITP). , 2013, Blood.

[106]  V. Kuchroo,et al.  MyD88 is essential to sustain mTOR activation necessary to promote T helper 17 cell proliferation by linking IL-1 and IL-23 signaling , 2013, Proceedings of the National Academy of Sciences.

[107]  R. Morita,et al.  Nr4a receptors are essential for thymic regulatory T cell development and immune homeostasis , 2013, Nature Immunology.

[108]  K. McCrae,et al.  Immune thrombocytopenia. , 2013, Hematology/oncology clinics of North America.

[109]  Yunfeng Cheng,et al.  The Ratio of Treg/Th17 Cells Correlates with the Disease Activity of Primary Immune Thrombocytopenia , 2012, PloS one.

[110]  J. Freedman,et al.  Thymic retention of CD4+CD25+FoxP3+ T regulatory cells is associated with their peripheral deficiency and thrombocytopenia in a murine model of immune thrombocytopenia. , 2012, Blood.

[111]  S. Kaveri,et al.  Inhibitory Effect of IVIG on IL-17 Production by Th17 Cells is Independent of Anti-IL-17 Antibodies in the Immunoglobulin Preparations , 2012, Journal of Clinical Immunology.

[112]  N. Shan,et al.  Increased Number of Tc17 and Correlation with Th17 Cells in Patients with Immune Thrombocytopenia , 2011, PloS one.

[113]  S. Kaveri,et al.  Comparison of different IVIg preparations on IL-17 production by human Th17 cells. , 2011, Autoimmunity reviews.

[114]  Hue Lee,et al.  Reduced expression of transforming growth factor‐β1 and correlated elevation of interleukin‐17 and interferon‐γ in pediatric patients with chronic primary immune thrombocytopenia (ITP) , 2011, Pediatric blood & cancer.

[115]  Kailin Xu,et al.  [Imbalance of Th17/Treg cells ratio in peripheral blood of patients with immune thrombocytopenia]. , 2011, Zhongguo shi yan xue ye xue za zhi.

[116]  W. Leonard,et al.  Cytokine receptor modulation by interleukin-2 broadly regulates T helper cell lineage differentiation , 2011, Nature immunology.

[117]  W. Shi,et al.  The transcription factors Blimp-1 and IRF4 jointly control the differentiation and function of effector regulatory T cells , 2011, Nature Immunology.

[118]  Kailin Xu,et al.  Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia , 2011, International journal of hematology.

[119]  R. Morita,et al.  Smad2 and Smad3 Are Redundantly Essential for the TGF-β–Mediated Regulation of Regulatory T Plasticity and Th1 Development , 2010, The Journal of Immunology.

[120]  J. O’Shea,et al.  Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. , 2010, Immunity.

[121]  S. Heck,et al.  Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. , 2009, Blood.

[122]  Jingru Zhang,et al.  Aberrant expression of Notch signaling molecules in patients with immune thrombocytopenic purpura , 2010, Annals of Hematology.

[123]  D. Vignali,et al.  Organization of proximal signal initiation at the TCR:CD3 complex , 2009, Immunological reviews.

[124]  A. Sharpe.  Mechanisms of costimulation , 2009, Immunological reviews.

[125]  Manuel Rubio,et al.  CD28 Co-Stimulation Down Regulates Th17 Development , 2009, PloS one.

[126]  J. Kolls,et al.  Interleukin-17A and interleukin-17F: a tale of two cytokines. , 2009, Immunity.

[127]  Yunfeng Cheng,et al.  Elevated Expression of IL-17 and IL-23 in Patients with Immune Thrombocytopenic Purpura , 2008 .

[128]  M. Kaplan,et al.  IL-23 Promotes Maintenance but Not Commitment to the Th17 Lineage1 , 2008, The Journal of Immunology.

[129]  M. Farrar,et al.  IL-2, -7, and -15, but Not Thymic Stromal Lymphopoeitin, Redundantly Govern CD4+Foxp3+ Regulatory T Cell Development1 , 2008, The Journal of Immunology.

[130]  S. Amadori,et al.  Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. , 2008, Blood.

[131]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[132]  Lai Wei,et al.  IL-21 Is Produced by Th17 Cells and Drives IL-17 Production in a STAT3-dependent Manner* , 2007, Journal of Biological Chemistry.

[133]  R. Treisman,et al.  Raf Signaling but not the ERK Effector SAP-1 Is Required for Regulatory T Cell Development1 , 2007, The Journal of Immunology.

[134]  Y. Shoenfeld,et al.  Intravenous Immunoglobulin Therapy Affects T Regulatory Cells by Increasing Their Suppressive Function , 2007, The Journal of Immunology.

[135]  C. Ruan,et al.  Circulating dendritic cells subsets and CD4+Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high‐dose dexamethasome , 2007, European journal of haematology.

[136]  D. Levy,et al.  IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways , 2007, Nature Immunology.

[137]  M. Hou,et al.  Correction of Th1-dominant Cytokine Profiles by High-dose Dexamethasone in Patients with Chronic Idiopathic Thrombocytopenic Purpura , 2007, Journal of Clinical Immunology.

[138]  M. Farrar,et al.  IL-2 Receptor β-Dependent STAT5 Activation Is Required for the Development of Foxp3+ Regulatory T Cells1 , 2007, The Journal of Immunology.

[139]  M. Topham,et al.  Disruption of diacylglycerol metabolism impairs the induction of T cell anergy , 2006, Nature Immunology.

[140]  L. Flowers,et al.  LAT-mediated signaling in CD4+CD25+ regulatory T cell development , 2006, The Journal of experimental medicine.

[141]  Ying Wang,et al.  A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17 , 2005, Nature Immunology.

[142]  Bin Zhou,et al.  Multi-dysfunctional pathophysiology in ITP. , 2005, Critical reviews in oncology/hematology.

[143]  T. Malek,et al.  Essential role for interleukin-2 for CD4+CD25+ T regulatory cell development during the neonatal period , 2005, The Journal of experimental medicine.

[144]  A. Singer,et al.  CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2 , 2005, Nature Immunology.

[145]  Z. Han,et al.  Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. , 2005, Haematologica.

[146]  M. Theodoropoulou,et al.  Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. , 2004, Blood.

[147]  M. Mahmoud,et al.  Serum IL-2 and platelet-associated immunoglobulins are good prognostic markers in immune thrombocytopenic purpura. , 2004, The Egyptian journal of immunology.

[148]  H. Amagai,et al.  High Th1/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura , 2003, European journal of haematology.

[149]  Tokiharu Takahashi,et al.  Expression of Notch ligands, Jagged1, 2 and Delta1 in antigen presenting cells in mice. , 2002, Immunology letters.

[150]  J. Freedman,et al.  Comparison of platelet immunity in patients with SLE and with ITP. , 2000, Transfusion science.